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Impact of HPV vaccination on outcome of cervical cytology
screening in Denmark—A register-based cohort study
Lise Holst Thamsborg1, George Napolitano 1, Lise Grupe Larsen2 and Elsebeth Lynge3
1 Department of Public Health, University of Copenhagen, Copenhagen 1014, Denmark
2 Department of Pathology, Zealand University Hospital, Roskilde 4000, Denmark
3 Nykøbing Falster Hospital, University of Copenhagen, Ejegodvej 63 DK-4800, Denmark
4vHPV vaccination has been tested in randomized controlled trials under almost ideal conditions, and studies of real-life use have
compared outcome between vaccinated and unvaccinated women from the same birth cohort and mostly before screening age. Here
we present the first—to our knowledge—evaluation of the impact of the 4vHPV vaccination in real life without selection bias in the
reported data. The study has been carried out by comparing the results after first cervical screening between an HPV-vaccinated and
an unvaccinated birth cohort, consisting of women born in Denmark in 1993 and 1983, respectively. Cytology data covering an 8-
year period, from the age of 15 (age of HPV-vaccination) to age 23 (age of invitation to first cervical screening), were retrieved from
the Danish National Pathology Register. Abnormal cytology, defined as atypical squamous cell of undetermined significance and
worse (ASCUS1) was detected in 9.4% of women born in 1993 as compared with 9.0% of women born in 1983; RR51.04 (95% CI
0.96–1.12), p5 .29. Detection of high-grade squamous intraepithelial lesion (HSIL) was statistically significantly lower in the 1993
than in the 1983 cohort, RR50.6 (95% CI 0.5–0.7), p< .0001, while the opposite pattern was seen for ASCUS RR51.4 (95% CI
1.2–1.6), p< .0001. The decrease in HSIL means that more women can be spared referral for colposcopy and biopsy. The increase of
ASCUS could be explained by transition from conventional to liquid-based cytology, but this observation requires further monitoring.
The ﬁrst human papillomavirus (HPV) vaccine was marketed
in 2006, and its use disseminated rapidly in high income coun-
tries. Marketing of the HPV vaccine followed randomized con-
trolled trials showing a close to complete protection against
vaccine-type-related high-grade cervical intraepithelial neopla-
sia (CIN21) in women vaccinated as HPV-na€ıve.1,2 The trials
evaluated the efﬁcacy of the HPV vaccine under almost perfect
conditions. Now, the ﬁrst birth cohorts of women HPV vacci-
nated as girls, and therefore vaccinated when most of them
were HPV na€ıve, approach screening age. This gives the oppor-
tunity to evaluate the effectiveness of the HPV vaccine in rou-
tine health care provided to the general population.
In Denmark, free HPV vaccination was introduced in Octo-
ber 2008 for girls born in 1993 to 1995. Since 2009, HPV
vaccination of girls turning 12 years has been part of the child
vaccination program.3 The quadrivalent HPV-vaccine
(4vHPV) Gardasil (Merck) was used in the Danish vaccination
program from 2008 to 2015.4 The coverage was high during
the ﬁrst years of the vaccination program; amongst girls born
in 1993 to 1995 around 80% had ﬁrst dose, and 70% were fully
vaccinated.5 A woman in Denmark is invited to cervical
screening from the age of 23 years.6 The ﬁrst birth cohort of
Danish women offered free HPV vaccination as girls thus
entered the cervical screening program in 2016.
The ﬁrst indication of a reduced risk of cervical cancer in
HPV-vaccinated women will be a decrease in detection of
cytological abnormalities. We report here on the outcome of
this ﬁrst screening round of women born in 1993. The objec-
tive was to determine the impact of the introduction of HPV
vaccination on cytological abnormalities. The predeﬁned
hypothesis was that women offered HPV vaccination as girls
had a better protection against developing cellular changes
and subsequently a lower risk of abnormal cytology than
women from unvaccinated birth cohorts.
Material and Methods
Study population
We conducted a population-based cohort study in Denmark using
national health register data. In Denmark, approval by the Danish
Data Inspective Agency (SUND-2016–22) serves as ethical
approval of register-based studies without contact with patients.
Since 1986, all Danish women turning 23 years have been
invited to cervical screening.7 The screening sample is taken
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by the general practitioner (GP), and analyzed for cytological
abnormalities at centralized pathology laboratories. Up until
2002, all laboratories used conventional, manually read cytol-
ogy. Transition to liquid-based cytology (LBC) and imaging-
assisted reading started in 2002, spread gradually, and these
technologies have since 2015 been used in all laboratories.8–10
Since 1997, reporting to the National Pathology Register
(NPR) has been mandatory for hospital laboratories, but it
only became mandatory for private pathologists in 2005.11
Since 2000, cytology samples from all Denmark, except
Copenhagen County, have been reported in hospital laborato-
ries, while Copenhagen County predominantly used private
pathologists.12 To ensure complete ascertainment of cytology
results, we excluded the Copenhagen County from the study.
We studied two closed cohorts. First, women born in 1993,
and living in Denmark all the time between 1 January 2009 and
1 April 2017 were included. This cohort had been offered free
HPV-vaccination at the age of 15 from October 2008, and was
ﬁrst invited to screening in 2016. Second, women born in 1983,
and living in Denmark all the time between 1 January 1999 and
1 April 2007 were included. This cohort had never been offered
free HPV vaccination, and was ﬁrst invited to screening in 2006.
Women from both birth cohorts living in or moving to Copen-
hagen County were excluded. End-of-study on 1 April 2017 was
based on the availability of screening data for the 1993 birth
cohort. By 1 April 2017, women born in December 1993 and
invited to screening in December 2016 would have had at least
three months to be screened following their invitation. The
pseudo-date of 1 April 2007 was used for the 1983 cohort to
ensure equal follow-up time for the two cohorts. In this study,
exposure is deﬁned as the offer of free HPV vaccination.
Data sources and outcomes
In Denmark, a unique personal identiﬁcation number is
assigned at birth or immigration to all persons, making it
possible to link data from different registers and to ensure
complete follow-up. Data on vital status, emigration and
addresses were retrieved from the Central Population Regis-
ter. Data on cervical cytologies was retrieved from the NRP,
where a sample was registered at the date it was received at
the laboratory (Supporting Information, A). To ensure inclu-
sion of samples analyzed by private pathologists, we supple-
mented with data from the National Health Services Register
(NHSR; Supporting Information, B). As this register is based
on reimbursement of services, it does not include information
on diagnoses, and date of reimbursement is registered instead
of date of service. Data on HPV-vaccination status were
retrieved from NHSR, which includes special codes for reim-
bursement of HPV vaccination within the child vaccination
program. Data on HPV vaccination outside the program
were retrieved from the Prescription Register, which includes
information on all prescribed and purchased drugs in Den-
mark (Supporting Information, C).
Our primary outcome was diagnosis at ﬁrst cytology. Sec-
ondary outcomes included proportion of women with a ﬁrst
cytology (any cytology), and age at ﬁrst cytology. In Den-
mark, SNOMED13 is used in coding of pathology specimens.
It is mandatory to assign both a T-code for topography and
an M-code for morphology. Cervical cytologies are deﬁned
by T-codes starting with T8X3*, see Supporting Information.
For morphology coding, the Bethesda classiﬁcation14 was
introduced in 2007 in Denmark and implemented gradually.
Therefore, especially for the 1983 birth cohort, cytologies
were coded using former classiﬁcation systems. These former
codes were converted to Bethesda codes using the conversion
table in the Danish Quality Assurance of the Cervical Cancer
Screening Program15 supplemented with recoding by an
expert pathologist (author LGL; Supporting Information D).
In the analysis, cytology was divided into ﬁve categories: (i)
negative for intraepithelial lesion or malignancy (NILM); (ii)
atypical squamous cells of undetermined signiﬁcance
(ASCUS) (in the analysis the small group of atypical glandu-
lar cells (AGC) was merged with ASCUS); (iii) low-grade
squamous intraepithelial lesion (LSIL); (iv) high-grade squa-
mous intraepithelial lesion (HSIL) (in the analysis the small
group of atypical squamous cells cannot exclude HSIL
(ASCH) was merged with HSIL); and (v) unsatisfactory sam-
ple. In case of more than one M-code per sample, a hierarchy
of diagnoses was applied where the most severe diagnosis
was chosen. A code of unsatisfactory was overruled by any
diagnosis. ASCUS1 was used for ASCUS and any more
severe diagnosis. Missing was assigned to samples analyzed
by private pathologists and with no diagnostic code.
Age at ﬁrst cytology was calculated from the date of birth
and the date of receiving the sample at the laboratory or
reimbursement date in case of samples with missing diagnos-
tic code. Age at HPV vaccination was calculated from the
date of birth and the date on reimbursement for ﬁrst HPV
vaccination within the child vaccination program and date of
purchase for self-paid vaccination outside the program. We
What’s new?
In women without prior exposure to human papillomavirus (HPV) infection, quadrivalent HPV (4vHPV) vaccine is associated
with a reduction in high-grade squamous intraepithelial lesions (HSILs) and atypical squamous cells of undetermined signifi-
cance (ASCUS). In this study, involving HPV-vaccinated and unvaccinated birth cohorts of women in Denmark, the authors
evaluated the impact of HPV vaccination on these same cytological abnormalities. The findings show that women who received
4vHPV vaccine as girls experienced no significant change in ASCUS1 at their first cytology. Incidence of HSILs, however, was
significantly lower in vaccinated women compared with women who did not receive the vaccine.
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deﬁned HPV-vaccinated women as those having had at least
one dose of the HPV vaccine.
Data on geographical distribution of the two cohorts were
tabulated from our retrieved data by study start for each of
the cohorts. Data on proportion of women with at least high-
school degree at the age of 22 years were retrieved from pub-
lic statistics.16 We searched the literature for data on self-
reported age at sexual debut. The most precise data were for
women born 1960–198717 and 1983–1997,18 respectively.
Data on proportion of girls sexually active at the age of 15
and on daily smoking at the age of 15 were retrieved from
the School Health Surveys.19,20
Statistical analyses
The study was conducted as a national, register-based cohort
study including all eligible women. No power calculation was
therefore performed prior to the initiation of the study.
Indication for cytology is not reported in the NPR, but
women screened before the age of 23 years are screened on
their own or their doctor’s initiative either as opportunistic
screening or based on symptoms. Hence, results were strati-
ﬁed by age at ﬁrst cytology. To avoid selection bias, our pri-
mary comparison was between the entire 1993 and the entire
1983 cohorts. However, in a subanalysis results for the 1993
birth cohort were stratiﬁed also by HPV-vaccination status.
Unsatisfactory cytology is more frequent in conventional
cytology than in LBC.21 We therefore restricted the compari-
son between the two cohorts of ﬁrst cytology to women with
a ﬁrst satisfactory sample.
Because we operated with closed cohorts of women with full
follow-up over the entire study period, incidence proportions
(IP) were calculated with corresponding Clopper–Pearson 95%
conﬁdence intervals (CI). Relative risks (RR) for the 1993 versus
the 1983 birth cohorts were calculated using v2 test with 95%
CI. p values of <0.05 were considered to be statistically signiﬁ-
cant. Pseudo-anonymized register data were accessed via the
research service of Statistics Denmark. SAS statistical software
version 9.4 (TS1M3) was used for the analysis.
Results
Study population
In total, 26,331 women were born in 1983 and lived in Den-
mark on January 1, 1999; of these, 6,870 women were
excluded from the study mainly because they lived in/moved
to the Copenhagen County (Table 1 and Supporting Infor-
mation, Figures E and F). In total, 34,140 women were born
in 1993 and lived in Denmark on 1 January 2009, and of
these, 8,662 women were excluded for the same reasons as
for the 1983 cohort. The percentage of excluded women was
similar, 26% for 1983 and 25% for 1993. The two study pop-
ulations included 19,461 and 25,478 women, respectively.
The 1983 cohort was smaller than the 1993 cohort. In the
beginning of the 1980s, the birth rate was in generally lower
than in the 1990s probably due to the economic crisis, and
in 1983, the birth rate hit a historical nadir.22
The distributions of women across the Danish regions
were fairly similar for the two birth cohorts, and so were the
proportions of women with at least a high-school degree at
the age of 22 years. The proportion of 15-year old girls
smoking daily decreased from 21% to 10%. The average age
at sexual debut was 16 years for both cohorts. It should
though be taken into account that the available data covered
a broad range of birth cohorts. In the 1993 cohort, 37% of
the girls reported to be sexually active at the age of 15 years.
In women born in 1993, 86% had been HPV-vaccinated
15 years, and 6% above this age (Table 2). These women
were all vaccinated with 4vHPV apart from three women
vaccinated with the bivalent HPV vaccine (2vHPV). The vast
majority were vaccinated through the child vaccination pro-
gram, while only a minority had purchased the vaccine them-
selves; 1381 women out of 23,330 vaccinated women. The
mean age of vaccination was 14.9 years. The proportion of
women with any cytology was fairly similar in the two
cohorts; 63% versus 61%; but cytology before age of invita-
tion to screening was more common in the 1983 than in the
1993 cohort, 27% versus 19%. While overall 38% of the vacci-
nated women in the 1993 cohort had no cytology, this was
the case for 55% of the unvaccinated women.
Cervical cytology
The proportion of unsatisfactory samples and samples miss-
ing pathology diagnoses decreased from 6% in the 1983
cohort to 1.2% in the 1993 cohort (Table 3 and Fig. 1). In
both cohorts, 60% of women had a satisfactory ﬁrst sample.
The mean age of ﬁrst cytology was 21.7 years for women
born in 1983 versus 22.1 years for women born in 1993.
Among these women, largely the same proportions, 9.0% in
the 1983 cohort and 9.4% in the 1993 cohort, had an abnor-
mal cytology deﬁned as ASCUS1; RR5 1.04 (95% CI 0.96–
1.12), p5 0.29. However, the risk of having HSIL was statisti-
cally signiﬁcantly lower in the 1993 than in the 1983 cohort,
RR5 0.6 (95% CI 0.5–0.7), p< 0.0001.
Among women with a ﬁrst cytology before the age of 23
years, the risk of an ASCUS1 result was more frequent in
the 1993 than in the 1983 cohort; the percentages being
11.8% and 9.3%, respectively; RR5 1.28 (95% CI 1.13–1.43),
p< 0.001 (Table 4 and Fig. 1). This excess risk derived pre-
dominantly from ASCUS; RR5 1.78 (95% CI 1.45–2.18). In
these women examined at young age, the proportions with
HSIL were almost similar; RR5 0.93 (95% CI 0.65–1.31),
p5 0.67. In women ﬁrst examined at regular screening age,
the risk of an ASCUS1 result was almost the same in the
two cohorts; RR5 0.94 (95% CI 0.85–1.04), p5 0.24. The
overall decline in proportion of women with HSIL derived
almost entirely from this oldest age group; RR5 0.49 (95%
CI 0.38–0.63), p <0.0001.
The HPV-vaccination coverage in our 1993 cohort was
much higher than the 78% ofﬁcially reported.5 We therefore
made two sensitivity analyses. First, we included Copenhagen
County under the assumption that this county might have
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lower vaccination coverage than the rest of the country, but
this was not the case. Second, our analysis was based on
women born in 1993 and present in Denmark from January
1, 2009 to April 1, 2017. If we included instead all women
born in 1993, present in Denmark in 2016, and vaccinated
within the child vaccination program, we reach a vaccination
coverage of 77.7%, similar to the ofﬁcially reported coverage
based on the same data. The difference between our 91.6%
and the ofﬁcial coverage of 78% can then be explained by
population movements, where some vaccinated women left
Denmark over the follow-up period and some unvaccinated
women entered Denmark. We furthermore included self-
purchased vaccine in calculation of coverage.
Among the 15,315 women in the 1993 cohort with a ﬁrst sat-
isfactory cytology result, 13,543 were HPV-vaccinated at age15
years; 815 at age >15 years, and 957 were unvaccinated (Table
5). The risk of ASCUS1 was lower in early vaccinated than in
unvaccinated women; RR5 0.78 (95% CI 0.65–0.93), p5 0.008.
This pattern was seen for all subdiagnoses, but the numbers for
unvaccinated women were small. The late vaccinated women
had the same risk of ASCUS1 as the unvaccinated women;
RR5 1.09 (95% CI 0.85–1.40), p5 0.5, suggesting that a larger
proportion of HPV non-na€ıve women is present in this group.
Discussion
Principal findings
In this study, we determined the impact of HPV vaccination
on cytology results in the Danish cervical screening program
at the latest at age 23 years, where women are ﬁrst invited to
screening. We compared results from a vaccinated cohort of
Table 1. Characteristics of study population
Characteristics Birth cohort 1983 Birth cohort 1993
Number of women1 26,331 34,140
-Excluded because living in or moving
to Copenhagen County
4,507 (17%) 6,029 (18%)
-Excluded for other reasons 2,363 (9%) 2,633 (8%)
Number of included women 19,461 25,478
Region of residence at study start2
Northern Denmark 2,647 (14%) 3,378 (13%)
Central Denmark 5,389 (28%) 7,011 (27%)
Southern Denmark 5,346 (27%) 6,786 (27%)
Zealand 3,268 (17%) 4,260 (17%)
Capital 2,811 (14%) 4,043 (16%)
High-school degree3 52% 57%
Age of sexual debut4 16 years 16 years
Sexually active at age 155 Not available 37%
Smoking daily at age 156 21% 10%
HPV-vaccinated7 0% 92%
1Number of women living in Denmark January 1, 1999/2009.
2Proportion of number of included women.
3Statistics Denmark: Proportion of women with at least high-school degree at age 22.
4Self-reported sexual debut age for women born 1960–1987 (median) and 1983–1997 (mean).
5Self-reported sexual activity at age 15 years for girls born in 1995.
6Self-reported smoking status at age 15 years for girls born in 1983 and 1995, respectively.
7HPV-vaccination status at 1 April 2007 and 2017, respectively.
Table 2. Age at first cytology and HPV vaccination in the study population
Age at first
cytology, years 1983 cohort
1993 cohort
Age at first HPV vaccination, years
<15 15 >15 Nonvaccinated Total
<20 1,771 (9%) 259 1,012 106 144 1,521 (6%)
20–22 3,587 (18%) 531 2,359 158 245 3,293 (13%)
231 6,946 (36%) 1,427 8,118 559 582 10,686 (42%)
No cytology 7,157 (37%) 1,766 6,412 623 1,177 9,978 (39%)
Total 19,461 (100%) 3,983 (16%) 17,901 (70%) 1,446 (6%) 2,148 (8%) 25,478 (100%)
1A few women turned 24 years before having their first cytology result.
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women born in 1993 with results from an unvaccinated
cohort of women born in 1983. The two cohorts had fairly
similar cervical cancer risk proﬁles apart from a decrease in
the proportion of daily smokers.
The introduction of HPV vaccination did not affect atten-
dance to screening; in both cohorts around 60% of women
had been screened at the latest at age 23 years. There was no
difference between the two cohorts in proportion of women
Table 3. Result of first cervical cytology in women offered HPV vaccination (1993) and women not offered HPV vaccination (1983)
1983, N519,461 1993, N525,478 1993 vs. 1983
Birth cohort
Number of women
with first samples, %
Excl. unsatisfactory
and missing, % (CI)
Number of women
with first samples, %
Excl. unsatisfactory
and missing, % (CI)
RR (CI) Excl. unsatis-
factory and missing
Any cytology 12,304
63.2%
11,564
59.4%
15,500
60.8%
15,315
60.1%
0.96 (0.95–0.98)4
p<0.0001
Diagnosis of first cytology
NILM 10,523
85.5%
10,523
91.0% (90.5–91.5)
13,879
89.5%
13,879
90.6% (90.1–91.1)
0.996 (0.989–1.003)
p50.29
ASCUS1 347
2.8%
347
3.0% (2.7–3.3)
644
4.2%
644
4.2% (3.9–4.5)
1.4 (1.2–1.6)
p <0.0001
LSIL 486
4.0%
486
4.2% (3.8–4.6)
622
4.0%
622
4.1% (3.8–4.4)
1.0 (0.9–1.1)
p50.56
HSIL2 208
1.7%
208
1.8% (1.6–2.1)
170
1.1%
170
1.1% (1.0–1.3)
0.6 (0.5–0.7)
p<0.0001
ASCUS1 1041
8.5%
1041
9.0% (8.5–9.5)
1436
9.3%
1436
9.4% (8.9–9.8)
1.04 (0.96–1.12)
p50.29
Unsatisfactory 568
4.6%
- 185
1.2%
- -
Missing3 172
1.4%
- 0
0%
- -
1Defined as ASCUS and AGC.
2Defined as HSIL and ASCH.
3Sample analyzed by private pathologist.
4RR for any cytology computed including unsatisfactory and missing diagnosis.
Figure 1. Detection of cervical abnormalities at first cytology result in an HPV-vaccinated cohort (1993) compared with a non-HPV-
vaccinated cohort (1983) in Denmark. Relative risk and 95% confidence intervals. [Color figure can be viewed at wileyonlinelibrary.com]
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with ASCUS1; this being around 9% in both cohorts. There
was, however, a statistically signiﬁcant drop of 40%, from
1.8% to 1.1%, in the proportion of women with HSIL.
In the interpretation of these ﬁndings four issues have to
be considered: HPV-vaccination coverage; prevalence of sex-
ual activity at age 15; prevalence of smoking at age 15; and
transition from conventional cytology to LBC. The efﬁcacy
of 4vHPV was tested in the FUTURE randomized con-
trolled trials. In these trials, the risk of an ASCUS1 cytol-
ogy result was reduced by 17.1%.23 The study included
women with no history of genital warts or abnormal cytol-
ogy; seronegative, HPV-DNA negative for HPV 6, 11, 16,
18 and for 10 other high risk HPV-types, and cytology nor-
mal at recruitment. Some differences between the settings
may explain why this decrease in ASCUS1 was not seen in
our data. First, vaccination coverage was not 100% but 92%
in our 1993 cohort. Second, not all women in our 1993
cohort were HPV-na€ıve at time of vaccination; 37%
reported to be sexually active at the age of 15 years, and
we will assume that all women vaccinated later were sexu-
ally active, and that sexually active women had a 46% prev-
alence of high risk HPV DNA.24 Then 21% (5((0.37 3
0.86)1 0.061 0.08) 3 0.46) of our 1993 cohort would have
been HPV non-na€ıve. But with these reservations we should
still have seen a decrease in ASCUS1 of about 13% (5
12 ((0.79 3 0.83)1 0.21)).
The lower smoking prevalence in the 1993 than in the
1983 cohort should if anything increase protection against
ASCUS1 in the younger cohort. In a Danish study, smoking
was associated with a hazard ratio of 1.32 for CIN31 in
high-risk HPV-positive women.25 If we assume that the same
hazard ratio would be applicable to the impact of smoking in
the risk of HSIL, the decrease in smoking prevalence from
21% in the 1983 birth cohort to 10% in the 1993 birth cohort
would have affected the risk of HSIL only marginally; from
1.8% to 1.7%. It is therefore clear that the observed decrease
to 1.1% cannot be explained by the difference in smoking
between the two birth cohorts.
The change from conventional cytology to LBC might,
however, have worked in the opposite direction. SurePath LBC
provides a better protection against cervical cancer than con-
ventional cytology.26 In Denmark, conventional cytology has
been replaced mainly by SurePath LBC, and the transition was
associated with a considerable increase in the proportion of
Table 4. Age-stratified results of first cytology, excl. unsatisfactory and missing
Birth cohort 1983 1993 RR 1993 vs. 1983 (CI)
Age <23 years at first cytology
Any cytology 4,957 4,705 0.72 (0.70 – 0.75)
p<0.0001
Diagnosis of first cytology
NILM 4497
90.7% (89.9–91.5)
4148
88.2% (87.2–89.1)
0.97 (0.95–0.98), p <0.0001
ASCUS 144
2.9% (2.5–3.4)
243
5.2% (4.6–5.8)
1.78 (1.45–2.18), p <0.0001
LSIL 250
5.0% (4.4–5.7)
256
5.4% (4.8–6.1)
1.08 (0.91–1.28), p50.38
HSIL 66
1.3% (1.0–1.7)
58
1.2% (0.9–1.6)
0.93 (0.65–1.31), p50.67
ASCUS1 460
9.3% (8.5–10.1)
557
11.8% (10.9–12.8)
1.28 (1.13–1.43)
p<0.0001
Age 23 years at first cytology
Any cytology 6,607 10,610 1.23 (1.20 – 1.26)
p<0.0001
Diagnosis of first cytology
NILM 6026
91.2% (90.5–91.9)
9731
91.7% (91.2–92.2)
0.94 (0.85–1.04)
p50.24
ASCUS 203
3.1% (2.7–3.5)
401
3.8% (3.4–4.2)
1.23 (1.04–1.45)
p50.01
LSIL 236
3.6% (3.1–4.0)
366
3.4% (3.1–3.8)
0.97 (0.82–1.13)
p50.67
HSIL 142
2.1% (1.8–2.5)
112
1.1% (0.9–1.3)
0.49 (0.38–0.63)
p<0.0001
ASCUS1 581
8.8% (8.1–9.5)
879
8.3% (7.8–8.8)
0.94 (0.85–1.04)
p50.24
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ASCUS1 in young women.8,9 It is, however, not possible to
quantify the possible impact of this change in technology. Cytol-
ogy samples for the women born in 1983 and included in this
study were taken with gradually increasing numbers from 1998
to 2006. Cytology samples for women born in 1993 were taken
from 2008 to 2016. For both birth cohorts, many laboratories
participated in the analysis of the samples, and the laboratories’
transition to LBC took place at different points in time between
2002 and 2015. This transition may therefore have overshad-
owed a possible effect of HPV vaccination on occurrence of
ASCUS1. The FUTURE studies showed a 44.5% (95% CI
4.3%–68.6%) decrease in HSIL in the intervention arm as com-
pared with the control arm.23 Our result of a 40% (95% CI
(30%–50%) decrease in HSIL is in line with the FUTURE result.
Furthermore, the FUTURE study showed high efﬁcacy of
the quadrivalent vaccine against genital warts.23 In Australia,
the incidence of genital warts decreased following the intro-
duction of the quadrivalent vaccine.27 A decrease was seen
also in Denmark from 2009.28 In principle, further indication
of vaccine effectiveness might be obtained from data on the
national time trend in detection of ASCUS. Such data have,
however, been reported only since 2013,29,30 showing a rela-
tive stable proportion about 3% with some variation across
the Danish regions.
Strengths and limitations
Our study was based on entire birth cohorts offered or not-
offered HPV vaccination, and on the outcome of cytology
after all women had been invited to the screening program.
We thus avoided the selection bias from comparing vacci-
nated with unvaccinated women, and the register data
ensured complete follow-up.
The study design included a temporal comparison of screen-
ing results 10 years apart. The results could therefore be con-
founded by changes in background risk over time. However, the
two cohorts had fairly similar cervical cancer risk proﬁles apart
from a decrease in smoking from the 1983 to the 1993 cohort,
and this decrease may be a possible confounding to be taken
into account. We had more women with unsatisfactory samples
in the 1983 birth cohort than in the 1993 birth cohort. Conven-
tional cytology samples may be unsatisfactory due to blood and/
or inﬂammation, and women with unsatisfactory samples are
recommended for retesting. However, in this study, we included
for simplicity only ﬁrst cytology samples. Blood and/or inﬂam-
mation are eliminated from LBC samples resulting in a lower
proportion of unsatisfactory samples.
Transition from conventional cytology to SurePath LBC
may in part explain the lack of an effect of HPV vaccination
on occurrence of ASCUS1. We have no Danish data for the
positive predictive value of HSIL for cervical intraepithelial
neoplasia (CIN)21. Changes from the 1983 to the 1993 birth
cohorts are unlikely, as the pathology departments have fol-
lowed the same diagnostic procedures throughout the study
period, but a possible diagnostic drift in HSIL associated with
the transition from conventional cytology to LBC cannot be
excluded. Screening coverage was only 60% in our 1993
cohort, but so it was in the 1983 cohort. In cervical screening,
the risk proﬁle of nonresponders differs from that of respond-
ers,31 and in our 1993 data, 94% of the screened women were
HPV vaccinated as compared with 88% of the nonscreened
women. Our results might therefore slightly overestimate the
effect of HPV vaccination. Somewhat surprisingly, the risk of
HSIL was not statistically signiﬁcantly decreased in vaccinated
as compared with nonvaccinated women in the 1993 birth
cohort. This might be due to herd immunity as overall 92% of
the birth cohort was vaccinated, as also suggested by virology
observations from Scotland.32,33 However, the number of non-
vaccinated women was small, and we do not know that sexual
activity before or at the age of 15 years was equally distributed
between vaccinated and nonvaccinated women. It should be
taken into account also that while 62% of the vaccinated
women in the 1993 birth cohort were screened, this was the
case for only 45% of the nonvaccinated women, as a similar
observation reported previously from Scotland34 and the
USA,35 although in different study designs. The follow-up
time was limited; thus, only 3 months for women invited to
screening in December 1993. The exclusion of Copenhagen
Table 5. Results of first cytology for 1993 birth cohort stratified by HPV vaccination status, excl. unsatisfactory and missing
Cytology diagnosis
Vaccinated 151
N513,543 (88.4%)
Vaccinated >151
N5815 (5.3%)
Unvaccinated
N5957 (6.3%)
15 vs. unvaccinated
RR (CI), p
>15 vs. unvaccinated
RR (CI), p
NILM 12,321 (91.0%) 712 (87.4%) 846 (88.4%) 1.03 (1.00–1.05)
p50.008
0.99 (0.95–1.02)
p5 (0.50)
ASCUS 552 (4.1%) 44 (5.4%) 48 (5.0%) 0.81 (0.61–1.08)
p50.16
1.08 (0.72–1.60)
p50.71
LSIL 531 (3.9%) 42 (5.1%) 49 (5.1%) 0.77 (0.58–1.02)
p50.07
1.00 (0.67–1.50)
p 50.97
HSIL 139 (1.0%) 17 (2.1%) 14 (1.5%) 0.70 (0.41–1.21)
p50.20
1.43 (0.71–2.87)
p50.32
ASCUS1 1222 (9.0%) 103 (12.6%) 111 (11.6%) 0.78 (0.65–0.93)
p50.008
1.09 (0.85–1.40)
p50.50
1Defined as at least one dose (22 women had first cytology before or on the date of the first HPV vaccination).
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County may limit generalizability, but does not affect the com-
parison between the two cohorts.
Other studies
The early impact of HPV vaccination on screening outcome
in Denmark has previously been reported for HPV-
vaccinated versus unvaccinated women born in 1993–1994 to
be a 60% (95% CI 44%–71%) decrease in atypia or worse.36
This study was, however, undertaken in a highly selected
population, as only 1.3% of the cohort had been screened at
the time of the investigation.
A systematic review of the real-world experiences of vacci-
nation with 4vHPV concluded that the estimates of the vac-
cine “effectiveness generally corresponded to vaccine efﬁcacy
from clinical trials”.37 It should though be taken into account
that most of the reviewed studies were prone to selection bias
as they compared vaccinated with unvaccinated women and
mostly reported on cervical abnormalities observed prior to
normal screening age. A study from Sweden thus reported a
63% (95% CI 51%–72%) decline in cervical intraepithelial
neoplasia (CIN)21 in women vaccinated when they were
16 years based on their screening outcome at the age of
13–22 years.38,39 This is a larger decline than seen in the
FUTURE studies,23 and it could probably be due to the selec-
tive character of study data as invitation to screening starts
only at the age of 23 years in Sweden.
In Australia, screening has been recommended from the
age of 18 or two years after start of sexual intercourse. A
comparison of women vaccinated when they were 16 years
with unvaccinated women reported a decline in any high-
grade histological abnormality of 38% (95% CI 12%–56%),40
which is in line with the FUTURE ﬁnding.23 The study
showed a decline in high-grade cytology of 36% (95% CI
5%–57%) and an insigniﬁcant decline in low-grade cytology
of 17% (95% CI 3%–33%); consistent with our results for
HSIL and LSIL.
Scotland is another country with an early start of screen-
ing age, and this country started vaccination with the bivalent
HPV vaccine in 2008. A comparison between women born in
1988; 99.95% unvaccinated; and in 1993; 22.98% unvacci-
nated; showed a decline of 54% (95% CI 47%–61%) in detec-
tion of CIN21 at the ﬁrst cervical screen at age 20 or 21.41
Given that vaccination coverage was partially only, this ﬁnd-
ing is in line with the results of the PATRICIA trial.42 Like
our study, the Scottish study avoided selection bias by com-
paring birth cohorts instead of comparing vaccinated and
unvaccinated women; and by using screening outcomes after
start of the regular screening age.
Implications
In Denmark, women with HSIL are referred for colposcopy
with biopsy.43 The observed reduction in risk of HSIL follow-
ing HPV vaccination implies that more than one third of the
previously referred women can be spared this procedure and
health care resources can be saved. Among the generations
born in the early 2000s, Denmark experienced a considerable
drop in HPV vaccination coverage due to concern over possi-
ble side effects,5 despite no evidence for a causal associa-
tion.44 Once this concern has settled, the fact that HPV
vaccination has the immediate beneﬁcial effect of sparing
women from referral to colposcopy may add to the incentive
for vaccination.
Future research
In this study, we focused on the very ﬁrst effect of HPV vac-
cination detectable after women vaccinated as girls entered
the screening program. The further follow-up of the cohorts
will focus on impact of vaccination on CIN and conization.
The lack of an impact of HPV vaccination on detection of
ASCUS was to some extent a puzzle although the transition
from conventional cytology to LBC is likely to have contrib-
uted. HPV triage of ASCUS is not undertaken in women
below the age of 30, but it would be of interest to explore the
HPV-type distribution in ASCUS samples from the HPV-
vaccinated women.
Conclusion
We presented data from a 4vHPV-vaccinated cohort com-
pared with an unvaccinated cohort from the time when they
had all been invited into the organized screening program.
The observed decrease in HSIL was a promising outcome of
the HPV vaccination.
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